Disclosure under Regulation 30 of SEBI Listing Regulations

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.5%1-day move

₹17100.00

prior close

₹18305.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.3-4.7-4.7-4.3-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0—

Up moveDown movePending

AI summary

Neuland Laboratories reported strong FY2026 consolidated results with revenue from operations growing 37% to ₹2,02,299 lakhs from ₹1,47,684 lakhs in FY2025. PAT jumped nearly 40% to ₹36,400 lakhs, while EPS improved to ₹283.71 from ₹202.74. The Board recommended a final dividend of ₹34 per share (340%). Statutory auditors issued an unmodified (clean) opinion with no going concern issues. The company also announced plans to invest ₹143.4 crores to expand capacity at Unit 1 by 120.5 KL over 12-18 months to meet growing customer demand, with an existing capacity utilization of 91%. Dr. Mauricio Futran was appointed as Additional Director (Non-Executive Non-Independent).

Likely market impact

The strong 37% revenue growth and 40% PAT growth indicate solid operational performance, which is positive for shareholders. The capacity expansion signals management confidence in sustained demand growth. The clean audit and consistent dividend payout reinforce financial stability.